Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and Diabetic Macular Edema

Opinion
Video

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

1:00 Suboptimal Response
6:30 Treatment Strategy
11:10 Response to New Therapies
14:00 Imaging for Monitoring
18:30 Role of Ang-2

Related Videos
Viability of Elamipretide for Geographic Atrophy in Dry AMD | Image Credit: HCPLive
Advancing Elamipretide into Phase 3 ReNEW and ReGAIN Trials | Image Credit: HCPLive
Elamipretide in ReCLAIM-2 Trial | Image Credit: HCPLive
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Linda Stein Gold, MD, and Bruce Strober, MD, PhD
Hong-Uyen Hua, MD; Sruthi Arepalli, MD; and Peter Kaiser, MD
© 2024 MJH Life Sciences

All rights reserved.